Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge

Cannabinoid receptor 1 (CB1R) has been one of the major targets in medication development for treating substance use disorders (SUDs). Early studies indicated that rimonabant, a selective CB1R antagonist with an inverse agonist profile, was highly promising as a therapeutic for SUDs. However, its ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Soler-Cedeno, Omar, Xi, Zheng-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600259/
https://www.ncbi.nlm.nih.gov/pubmed/36291128
http://dx.doi.org/10.3390/cells11203262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600259/
https://www.ncbi.nlm.nih.gov/pubmed/36291128
http://dx.doi.org/10.3390/cells11203262

Ejemplares similares